Business Wire

AccelStor Revs Up NeoSapphire All-Flash Array Portfolio for Next Generation Cloud Application

Jaa

AccelStor, the software-defined all-flash array provider, is pleased to announce its participation in this year’s Cloud Expo Europe at Frankfurt, Germany and will showcase its latest NeoSapphire H510 and NeoSapphire P710 all-flash array systems. The NeoSapphire P710 and H510 address different segments of the cloud and data centre markets to help organisations and enterprises maximize the value of their data. AccelStor will be exhibiting alongside over 200 vendors at the two-day event, as well as hosting a talk on the benefits of FlexiRemap® technology and the future of NVMe based solutions, and their benefits to the IaaS, Hosted VDI and Business intelligence applications. AccelStor can be found at Cloud Expo Europe (booth #730), at Messe Frankfurt, Germany on November 28-29.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171127005048/en/

AccelStor will demonstrate its latest NeoSapphire H510 all-flash array at Cloud Expo Europe in Frank ...

AccelStor will demonstrate its latest NeoSapphire H510 all-flash array at Cloud Expo Europe in Frankfurt on Nov. 28-29. (Photo: Business Wire)

AccelStor will be presenting its latest line of All-Flash products, including the showcase of a brand-new system built on the shared-nothing architecture, with 99.9999% uptime thanks to its true zero point of failure design. The NeoSapphire H510 is the first in the new generation of all-flash technology from AccelStor. The unique shared-nothing design and AccelStor’s patented FlexiRemap® technology, as well as outstanding performance mean AccelStor has many new features to show. AccelStor will be showing a live, interactive demo at Cloud Expo Europe, with a real-time performance monitor and a chance to see the UI in action.

AccelStor Vice President, David Kao, said: “We see enterprises being forced to make a trade-off between performance, capacity and cost in their business-critical applications. AccelStor recognises the need for a new innovator in the all-flash market, aimed directly at the data centre, cloud and artificial intelligence markets. Both the NeoSapphire H510 and P710 are geared towards the unique requirements of the modern enterprise by offering the highest levels of performance and redundancy, no licensing and an unbeatable dollar per IOPS price tag.”

All the NeoSapphire products come with the patented FlexiRemap® technology. FlexiRemap® ensures data protection by increasing drive endurance, while accelerating random-access speed. This innovative technology leverages several unique algorithms to challenge the legacy of RAID, its global wear-leveling algorithm increases drive lifetime by 200%, twice the endurance of typical legacy RAID 5 flash systems. FlexiRemap® also utilizes the true potential of SSD’s and can offer a 290% average increase in performance over the traditional RAID 5 algorithm by reordering incoming data for maximum performance.

In addition to FlexiRemap®, the NeoSapphire product range features a rich suite of free software features including Free Clone, thin provisioning, thick provisioning, Replication, Free Clone, Snapshot, Snapshot Backup and FlexiDedupe™, all pre-bundled with each system in order to provide the best redundancy and data protection at the best price.

Additional Resources

Download the NeoSapphire H510 Product Sheet; NeoSapphire P710 Product Sheet
Learn more about the NeoSapphire all-flash array series
Learn more about FlexiRemap® Technology
Follow AccelStor on Twitter: @AccelStor
Follow AccelStor on LinkedIn

About AccelStor, Inc.

AccelStor is accelerating the paradigm shift from conventional disk arrays to modern all-flash storage. AccelStor's NeoSapphire all-flash arrays, powered by FlexiRemap software technology, deliver sustained high IOPS for business-critical applications. With streamlined storage management, multi-protocol support, and front-access, hot-swappable solid-state drives, the NeoSapphire series promises to resolve performance bottlenecks for I/O-intensive applications like artificial intelligence, IoT, data centre, virtualization, high-performance computing, database, media processing, fintech and gaming. For more information about AccelStor and NeoSapphire, please visit www.accelstor.com.

AccelStor, FlexiRemap and NeoSapphire are trademarks or registered trademarks of AccelStor, Inc. in the United States of America and/or other countries.

* IOPS test results mentioned in this press release are generated by AccelStor and may vary in different test environments.

Contact information

AccelStor, Inc.
Clara Lee, +886 2 77467616 ext. 2561
clara.lee@accelstor.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 16:00Tiedote

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice

Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 15:47Tiedote

The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i

Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 13:18Tiedote

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,

Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament11.12.2017 12:41Tiedote

The Arab Inter-Parliamentary Union (AIPU) has honored Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the United Arab Emirates parliament, with the Parliamentarian Excellence Award in the Presidents of Arab Parliaments category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005411/en/ Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the UAE parliament (Photo: AETOSWire) The award honors Al Qubaisi as ‘first female leader of a parliament in the Arab world’, celebrating her achievements on a national, regional and global scale, as well as the accomplishments made by FNC under her leadership. It also acknowledges the pioneering parliamentarian initiatives, projects and programs she has spearheaded and her significant contr

Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma11.12.2017 11:00Tiedote

New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were presented this weekend at the 59th American Society of Hematology (ASH) Annual Meeting. The results showed that rapid infusion of CT-P10 was well-tolerated across all patient groups and patients could be safely switched from reference rituximab to CT-P10 without reverting to slower infusion rates1. The independent study examined the infusion-related reactions (IRRs) in three different patient groups: rituximab naive, those switching directly from reference rituximab to CT-P10, and those that received their last dose of reference rituximab at least 6 months prior to the study.1 The administration of rituximab is associated with IRRs which occur most frequently during the first infusion. To reduce the risk of IRRs, it is the man

Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services11.12.2017 11:00Tiedote

The Austrian Financial Market Authority (FMA) granted a license under the Payment Service Act to DIMOCO Payment Services . The awarded license allows DIMOCO Payment Services to contribute to the payment value chain, offering merchants a single technical interface and a unified clearing & settlement process for many payment methods, including credit cards, online bank transfers, SEPA and direct debit cards. “We differ from most PSPs in the global payments ecosystem with our personal touch,” said Boris Kersten, Managing Director of DIMOCO Payment Services. “We proactively and personally monitor the overall payment process. In addition to monitoring individual transactions, we make recommendations and take actions to decrease chargebacks and fraudulent transactions. This process is not simply left to algorithms, the human element is added to the mix resulting in the protec

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme